drugset / Trial / NCT05294731
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy expansion cohorts
Timeline
- Start
- 2022-05-06
- Primary completion
- 2029-01-31
- Completion
- 2029-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BGB-16673 | Other / unclassified | — | Oral |
Indications
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma
Richter transformation
Waldenstrom macroglobulinemia
chronic lymphocytic leukemia/small lymphocytic lymphoma
follicular lymphoma
mantle cell lymphoma
marginal zone lymphoma